e-Article
Final results from a randomized phase II study with single agent gemcitabine (G) and docetaxel (D) given sequentially every 3 weeks in advanced NSCLC
Document Type
Academic Journal
Author
Source
Annals of Oncology. Oct 01, 2002 13 Suppl 5:145-145
Subject
Language
English
ISSN
0923-7534